Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of CREG protein

A protein and use technology, applied in the field of medical use of CREG protein

Inactive Publication Date: 2016-02-17
GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no studies have shown that CREG protein can be used as a target for AS treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of CREG protein
  • Medical application of CREG protein
  • Medical application of CREG protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1. Amplification and titer determination of recombinant human CREG adenovirus (AdCREG)

[0039] AdCREG was preserved in the China Type Culture Collection Center (CCTCC, Wuhan, Wuhan University) on January 2, 2008. The name is human adenovirus type 5 Ad5-CREG, and the preservation number is CCTCC-V200801 (see Chinese patent CN101475961A, invention name: Recombinant adenovirus expressing human CREG and use thereof). Incubate 5×10 in DMEM containing 5% fetal bovine serum 6 Ad293 cells (human embryonic kidney cells, purchased from Stratagene, USA, Cat. No. #240085). Take 0.5 μl of AdCREG virus preservation solution, add DMEM containing 5% fetal bovine serum to 1 ml, and mix well to obtain a virus mixture. Remove the culture medium of Ad293 cells, carefully add the virus mixture, and shake slowly 3 times in a cross shape. placed at 37°C CO 2 After incubating in the incubator for 120 min, 9 ml of DMEM culture solution containing 5% fetal bovine serum was added,...

Embodiment 2

[0043] Example 2. Preparation of atherosclerosis mouse model

[0044] 8-week-old ApoE gene knockout (ApoE - / - ) mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), were given high-fat feeding after weaning. High-fat feed formula: 15% fat, 0.25% cholesterol, 84.75% common feed. The mouse model of atherosclerosis was prepared after continuous feeding for 8 weeks. The experimental results showed that compared with the blood vessels of normal mice, apoE- / - mice could see obvious atherosclerotic plaque protruding into the lumen after 8 weeks of high-fat feeding. Visible lipid vacuoles, cholesterol crystals, a large number of inflammatory cell infiltration ( figure 2 ). The above results indicated that the mouse model of atherosclerosis was successfully prepared.

Embodiment 3

[0045] Example 3. Tail vein injection of adenovirus for the treatment of atherosclerosis

[0046] The ApoE- / - mice with atherosclerosis were randomly divided into AdCREG group (n=20), AdGFP group (n=20) and normal saline control group (n=20) after continuous high-fat feeding for 8 weeks. The number of mice for each index is 3-5. In the AdCREG group, the titer was 4.75×10 by tail vein injection. 10 1 ml of saline containing 1 viral plaque forming unit (PFU) of AdCREG. In the AdGFP group, the titer was 4.75×10 by tail vein injection. 10 PFU of AdGFP in 1ml of saline. The normal saline control group was injected with 1ml of physiological saline through the tail vein. After continuing to feed for 8 weeks, the mice were sacrificed by neck dislocation, and the aorta blood vessels were taken.

[0047] For the blood vessels that have been taken, the infection efficiency of the recombinant adenovirus was identified. In the present invention, the recombinant adenovirus AdGFP has a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Titeraaaaaaaaaa
Login to View More

Abstract

The invention relates to medical application of CREG protein, and in particular relates to application of the CREG protein in preparing a medicine or a medical instrument for preventing and / or treating atherosclerosis or atherosclerosis related diseases (such as coronary heart disease, cerebral apoplexy, abdominal aortic aneurysm and peripheral arterial disease). The invention also relates to application of a recombinant vector for expressing the CREG protein, a recombinant cell containing the recombinant vector, and a preparation capable of inhibiting down-regulation of the expression of the CREG protein inside blood vessel and capable of up-regulating the expression level of the CREG protein side the blood vessel in preparing a medicine or a medical instrument for preventing and / or treating atherosclerosis or atherosclerosis related diseases (such as coronary heart disease, cerebral apoplexy, abdominal aortic aneurysm and peripheral arterial disease).

Description

technical field [0001] The present invention relates to the medical use of CREG protein, in particular to the use of CREG protein in the preparation of medicines or medical devices for preventing and / or treating atherosclerosis or atherosclerosis-related diseases (such as coronary heart disease and stroke). The present invention also relates to a recombinant vector expressing CREG protein, a recombinant cell containing the recombinant vector, a preparation capable of inhibiting the down-regulation of CREG protein expression in the blood vessel wall or up-regulating the expression level of the CREG protein in the blood vessel wall. Use in drugs or medical devices for atherosclerosis or atherosclerosis-related diseases (eg coronary heart disease, stroke). Background technique [0002] Atherosclerosis (AS) is the most common type of sclerotic vascular disease. With the improvement of people's living standards, changes in lifestyle and prolongation of life expectancy, the incid...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/17A61K48/00A61P9/10A61L31/16
Inventor 韩雅玲闫承慧田孝祥孙鸣宇杨桂棠陶杰康建
Owner GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com